Use of Tranexamic Acid to Reduce Postoperative Blood Transfusion in Total Hip Replacement Surgery: A Prospective Study

Saleh Mohammed Kagzi1, Nazmuddin Jetaji1*, R N Laddha2, Naveen Rathor3

ABSTRACT

Background: Total hip replacement surgery is one of the most advanced and technically demanding surgeries in orthopaedics in which blood loss is inevitable. Most of the patients are elderly with multiple co morbidities and the estimated one-year mortality is about 25%. Objective of the study was to assess the need of post-operative blood transfusion in total hip replacement surgery in patients given tranexamic acid versus control.

Methods: It was a randomized controlled trial. Sixty patients of both sexes undergoing total hip replacement surgery included in study on the basis of inclusion and exclusion. Equal patients 30-30 (50%) divided in two groups Tranexamic Acid group and Control Group based on a computer-generated random number table. The Tranexamic Acid group received two doses of 10mg/kg body weight of tranexamic acid just before surgery and two hours later intravenously, whereas Control group received two doses of 10mg/kg body weight of normal saline at similar intervals. Numbers of blood transfusions required postoperatively were noted based on the postoperative haemoglobin readings.

Results: Mean post-op haemoglobin for the Tranexamic acid group was 10.1±2.6 g/dl and for the Control group it was 9.1±2.4 g/dl. Seven patients (23%) in intervention group required blood transfusion compared to 13 (43%) in control group.

Conclusions: Our study revealed that Perioperative Tranexamic acid is a safe and useful method of reducing intra op bleeding and need of post-operative blood transfusion postoperatively in THR patients.

Keywords: Blood transfusion, THR, TXA

INTRODUCTION

Total Hip Replacement surgery is one of the most demanding surgery in orthopaedics in which blood loss is inevitable. This is also an advance surgery. Most of the patients belongs to elderly group with multiple co morbidities and the estimated one-year mortality is about 25%.[1] It has been estimated that around 50% of patients undergoing hip surgery require at least 1100 ml of blood transfusion.[2] Blood transfusion also has its demerits like it can cause severe immunological reactions and also be a source of various blood-borne infections.[3] Various methods available now a days to decrease intraoperative blood loss are permissive hypotension, topical freezing saline, thromboplastic agent and intraoperative administration of anti-fibrinolytic agent like tranexamic acid (TXA).[4] TXA is a pharmacological agent, and is a derivative of amino acid lysine which occupies lysine sites on the plasminogen molecules and therefore causes reduced formation of activated plasmin which is responsible for the dissolution of clot. This in turn results in stabilization of clot and decreased blood loss. Use of TXA has been extensively studied in cardiac, spine, maxillofacial and other surgeries and has been proved to be an important factor in decreasing operative blood loss and hence, the need for postoperative blood transfusion.[5,6] With limited literature for

How to cite this article: Kagzi SM, Jetaji N, Laddha RN, Rathi n R. Use of Tranexamic Acid to Reduce Postoperative Blood Transfusion in Total Hip Replacement Surgery: A Prospective Study. Int Arch BioMed Clin Res. 2018;4(1):149-151.

Source of Support: Nil, Conflict of Interest: None
when TXA was administered compared to when placebo was administered,

### METHODS

This study was conducted in the Department of Orthopaedics, Pacific Medical College and Hospital, Udaipur. After approval from institutional ethical committee (IEC), Sixty patients of both sexes undergoing THR surgery were included in study according to inclusion and exclusion criteria after getting written and informed consent. Patients having ischemic heart disease, pregnant or lactating women, those with known coagulation disturbances, use of warfarin or other anticoagulants and allergy to TXA were excluded from study. Only those providing consent to participate in the study were enrolled in the study.

Equal patients 30-30 (50%) were divided in two groups Tranexamic acid group and Control group based on a computer-generated random number table.

### Groups

- **Tranexamic acid group (30)**
- **Control group (30)**

Dose administered in both the groups was 10mg/kg body weight, where one group received two doses of 10mg/kg body weight of tranexamic acid just before surgery and two hours later intravenously, whereas Control group received two doses of 10mg/kg body weight of normal saline at similar intervals. Neither the patient nor the investigator knew of the group allocation. Haemoglobin (Hb) was measured preoperatively (pre-op Hb) and at 24 hours postoperatively (post-op Hb). All the patients were operated by the authors only. Patients who were required to receive blood transfusion were noted. Blood was transfused if the postoperative Hb was <8g/dl.

Statistical Analysis was done with the help of Excel.

### RESULTS

Out of 60 participating patients in study equal number of 30-30 (50%) divided in two groups Tranexamic acid group and control group. There were no significant differences between the groups in terms of age (55.8±9.7 years in TXA group ranging from 29-86 years while 62.6±9.2 years in Control group ranging from 33 years to 81 years), gender (F/M 28/22 and 29/21 in respective groups), site (R/L 16/14 and 20/10 in respective groups), pre-op Hb (10.6±1.6 gm% and 11.8±1.5gm% in respective group) and duration of surgery (Table 1). Mean post-op haemoglobin for the tranexamic acid group was 10.1±2.6 g/dl and for the control group it was 9.1±2.4 g/dl Seven (23%) in intervention group required blood transfusion compared to 13 (43%) in control group (Table 1). The relative risk (RR) for transfusion was 0.51 when TXA was administered compared to when placebo was administered.

### DISCUSSION

Benoni G et al. conducted a study to assess the role of TXA in total knee replacement (TKR). Two doses of 10mg/kg body weight of TXA were administered, one before release of tourniquet and the second three hours later. Giving TXA significantly reduced the amount of blood loss and the need for blood transfusion.[1] A meta-analysis of 129 RCTs, carried out in 2012 also concluded that the probability of receiving transfusion after surgery was reduced by one-third after administering TXA.[2] Vijay et al did a RCT in which TXA was administered as an initial bolus dose of 500mg before surgery followed by continuous infusion at 1mg/kg/h for the duration of surgery. Results showed that the differences in mean reduction in Hb and mean volume of blood loss postoperatively between TXA and placebo groups were significant. In addition, only 7 out of 30 patients in TXA group required blood transfusion compared to 13 out of 30 in placebo group and the difference was again significant. In contrast to this another RCT done by Zufferey et al in 2010 showed that there was no significant difference in blood transfusion rates between TXA and placebo groups after surgery for hip fracture.[3] Therefore, although effectiveness of TXA in reducing post-surgical blood loss and transfusion requirements have been shown by multiple studies, but its effectiveness, specifically in hip surgeries, is yet to be established. Our study showed that in THR the need for blood transfusion was significantly reduced in patients receiving TA, as 23% patients in TXA group versus 43% in control group required blood transfusion our results are comparable to a study of Vijay et al in which 15.5% patients in TXA group and 40% in control group required transfusion after hip fracture surgery.[4]

In present study no complication occurred in the TXA group, which is also supported by a meta-analysis conducted in 2003 which concluded that TXA is not associated with an increased risk of thrombo embolic accidents.[5] TXA is a low cost and relatively safe alternative to reduce need of postoperative blood transfusion in THR surgery. This ultimately helps in decreasing the financial load on the patients. In spite of the fact that certain confounding factors could have had an effect on the efficacy of results of the study like BMI, but still this study does not fail in proving the usefulness of TXA. The study also takes into account only the post-op Hb measured 24 hours after surgery. To further substantiate the results, the volume of blood loss intra operatively and postoperatively can also be measured. Hb levels can also be measured daily for a week after surgery to evaluate the long-term effect of TXA.

### CONCLUSION

Perioperative tranexamic acid is a safe and useful method of reducing intra operative bleeding and need of blood transfusion post operatively in total hip replacement patients.

### REFERENCES